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Abstract: Voriconazole is a new triazole developed for the treatment of life-threatening
fungal infections. The drug is available for both oral and intravenous administration; the oral
formulation has excellent bioavailability. The side-effect profile of voriconazole presents an
acceptable safety and tolerability spectrum: transient visual disturbances, liver enzyme
abnormalities, and skin rashes are the most frequently reported side effects but rarely lead to
discontinuation. The potential for drug–drug interactions is high, because of its extensive
hepatic metabolism. Careful attention to dosage is required, and serum levels and the effects
of interacting drugs should be monitored. Review of 25 470 isolates of yeasts and 3216 isolates
of filamentous fungi showed voriconazole to have broad-spectrum activity against pathogenic
yeasts including intrinsically fluconazole-resistant isolates such as Candida krusei, dimorphic
fungi, and opportunistic moulds like Aspergillus spp, amphotericin-B-resistant Aspergillus
terreus, Fusarium spp, and Scedosporium apiospermum. It displays excellent clinical efficacy
in patients with fluconazole-resistant and -susceptible Candida infections, invasive bone and
central nervous system aspergillosis, and various refractory fungal infections. Voriconazole
has been approved by the US Food and Drug Administration and by the European Medicines
Agency for the treatment of invasive aspergillosis, serious infections caused by Fusarium
and S. apiospermum, fluconazole-resistant invasive Candida infections, and candidemia in
nonneutropenic patients.
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Background
Over the past few decades, the number of patients at risk of developing a serious
fungal infection has increased dramatically because of the more potent
immunosuppressant therapies used for transplantation, cancer, and other medical
conditions, and the rising number of patients with additional risk factors (central
venous catheters, broad-spectrum antibiotics, or aggressive surgery), together with
the AIDS epidemic. However, despite the introduction in the early 1990s of
fluconazole (Diflucan
®, Pfizer Inc, New York, NY, USA), itraconazole (Sporanox
®,
Janssen-Cilag Ltd, Beerse, Belgium), and lipid formulations of amphotericin B,
mortality from disseminated fungal infections continues to be unacceptably high.
Despite the advantages of these newer drugs over the older antifungal agents
(lower toxicity and a broader spectrum of activity), each drug has its own limitations.
Fluconazole is not effective against pathogenic moulds such as Aspergillus spp or
Fusarium spp; in addition, some non-Candida albicans species such as C. krusei
and C. glabrata exhibit fluconazole resistance. Itraconazole has a broader spectrum
of activity than fluconazole, but its oral bioavailability is unpredictable and the
intravenous formulation is not yet available in some countries. Amphotericin B has
broad-spectrum activity, but its use is associated with nephrotoxicity and infusion-
related reactions. Although less toxic, the high cost of lipid formulations such as
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liposome-encapsulated amphotericin B (Ambisome®, Gilead
Sciences, Foster City, CA, USA) and amphotericin B–lipid
complexes (Abelcet
®, Enzon Pharmaceuticals, Bridgewater,
NJ, USA), has limited their practical use.
Voriconazole (Vfend
®, Pfizer Ltd, New York, NY, USA)
belongs to a second generation of triazoles and was developed
to fulfill the need for a broad-spectrum antifungal agent with
both oral and intravenous formulations. This drug is a synthetic
derivative of fluconazole, with fungicidal activity against
moulds and excellent pharmacokinetics. It is widely distributed
in body fluids, including the cerebral spinal fluid (CSF). It is
generally well tolerated, and the reported side effects rarely
lead to the drug therapy being discontinued.
Voriconazole was approved by the US Food and Drug
Administration (FDA) in May 2002 for the treatment of
invasive aspergillosis and serious infections caused by
Fusarium spp and Scedosporium apiospermum in cases of
intolerance of or refractoriness to other antifungal agents.
In November 2003, a license was granted for its use in the
treatment of esophageal candidiasis. In December 2004,
voriconazole was approved for the treatment of candidemia
in nonneutropenic patients, disseminated candidiasis, and
Candida infections of the abdomen, kidney, bladder wall,
and wounds (FDA 2001). In Europe, voriconazole has been
approved by the European Medicines Agency (EMEA) since
March 2002 for the treatment of invasive aspergillosis,
fluconazole-resistant invasive Candida infections, and
serious infections caused by Scedosporium spp and
Fusarium spp (EMEA 2002). Recently, in January 2005,
the EMEA approved an extension of these indications to
include the treatment of candidemia in nonneutropenic
patients (EMEA 2005).
Chemistry
Voriconazole (2R,3S 2-[2,4-diflurophenyl]-3-[5-
fluropyrimidine-4-yl]-1-[1,2,4-triazol-1-yl] butan-2-ol) is a
broad-spectrum triazole antifungal agent with the molecular
formula C16H14N5OF3 and a molecular weight of 349.3.
Voriconazole was developed by the structural modification
of fluconazole, with the substitution of a triazole moiety
with a fluoropyrimidine ring and the addition of an α-methyl
group to the propyl backbone (Figure 1) (Sabo and Abdel-
Rahman 2000; Donnelly and de Pauw 2004; Herbrecht
2004).
The addition of the α-methyl group increased the affinity
of voriconazole for the target enzyme. A fluconazole
concentration of 4.8 µM is required to inhibit 50% of the
enzyme activity (IC50) of Aspergillus fumigatus, whereas
only 0.48 µM voriconazole is required. Furthermore, the
fluoropyrimidine ring increases its antifungal potency, and
the addition of fluorine to this ring structure at the 5 position
enhances its in vivo efficacy (Sabo and Abdel-Rahman 2000;
Herbrecht 2004; Sadaba et al 2004).
Voriconazole is a white to light-colored powder and
its solutions (1 mg/mL) can be made up in dimethyl
sulfoxide (DMSO) for animal experiments. The drug is
available for oral administration as tablets (50 mg or
200 mg) and powder for oral suspension (40 mg/mL).
Voriconazole has limited aqueous solubility. Therefore,
the intravenous formulation is combined with solubilizing
sulfobutyl ether β-cyclodextrin sodium (SBECD). This
agent is pharmacologically inert, does not affect the
pharmacokinetics of voriconazole, and is renally cleared
at a constant rate by glomerular filtration (Pearson et al
2003; Herbrecht 2004).
Figure 1 Structural formulae of fluconazole and voriconazole.Therapeutics and Clinical Risk Management 2006:2(2) 131
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Pharmacodynamics and
pharmacokinetics
Its structural characteristics provide voriconazole with
fungicidal activity against Aspergillus spp and other moulds.
Like other azole drugs, voriconazole exerts its mechanism
through the inhibition of the fungal cytochrome P450-
dependent enzyme lanosterol 14-α-demethylase (CYP51).
A critical step is thus inhibited in the sterol biosynthesis
pathway necessary for the production of a functional fungal
membrane, as well as sustained growth. Voriconazole also
suppresses 24-methylene dihydrolanasterol demethylation
in some yeasts and filamentous fungi, explaining in part its
activity against fluconazole-resistant moulds (Sabo and
Abdel-Rahman 2000; Chandrasekar and Manavathu 2001;
Sadaba et al 2004).
The doses recommended for adults by FDA-labeled
indication are shown in Table 1. The intravenous regimen
consists of loading doses of 6 mg/kg bid for the first day,
followed by a maintenance dose of 4 mg/kg bid. Patients
may be switched to a maintenance dose of oral voriconazole
of 200 mg (≥40 kg bodyweight) or 100 mg (<40 kg
bodyweight) every 12 hours. Oral doses (tablets and
suspension) should be taken at least 1 hour before or after
meals, because food reduces the rate and extent of absorption
(bioavailability reduced by 22%). Reductions in maximum
concentration (Cmax) of 34% and in the area under the curve
(AUC) of 24% have been reported after a high-fat meal.
Both oral and intravenous maintenance doses can be
increased by 50% in patients with refractory disease
(Muijsers et al 2002; Donnelly and de Pauw 2004; Herbrecht
2004; Klasko 2005).
In adults, voriconazole displays nonlinear
pharmacokinetics, with a greater than proportional increase
in plasma concentration with dose escalation and a two-
compartment model of distribution. This is thought to be
related to its saturable, first-pass metabolism and reduced
systemic clearance. Voriconazole displays good oral
bioavailability and widespread tissue penetration, with
hepatic metabolism and renal excretion of its metabolites
(Jeu et al 2003; Johnson and Kauffman 2003; Pearson et al
2003). Unlike some triazole agents, absorption of
voriconazole is not affected by gastric pH. The comparative
pharmacokinetic characteristics of voriconazole are
summarized in Table 2.
In healthy subjects, a 2.5-fold and a 2.3-fold increase in
the AUC occur when an oral dose of 200 mg bid is increased
to 300 mg bid or an intravenous dose of 3 mg/kg bid is
increased to 4 mg/kg bid, respectively (Klasko 2005). An
analysis of 10 clinical trials (n = 280) detected no direct
relationship between mean, maximum, or minimum plasma
voriconazole levels and efficacy. Furthermore, most
opportunistic fungal pathogens are inhibited in vitro by
0.5 mg/L or less, which can usually be achieved with doses
of 3–6 mg/kg bid intravenously or 200 mg bid orally
(Radford et al 1997; Espinel-Ingroff 1998).
Table 1 Recommended voriconazole doses for adults (Klasko 2005)
Administration route FDA-labeled indication Dose
Intravenous Invasive aspergillosis, fusariosis, Loading dose 6 mg/kg every 12 hours for two doses, followed 4 mg/kg every 12
and scedosporiosis (Fusarium hours. Dose may be reduced 3 mg/kg every 12 hours if patient is unable to tolerate
spp and Scedosporium treatment.
apiospermum). Efficacy has been demonstrated with a duration of 6–27 days, then orally for 4–24
weeks in immunocompromised patients with invasive aspergillosis.
Candida infections. Loading dose 6 mg/kg every 12 hours for two doses.
Maintenance dose 3 mg/kg every 12 hours as primary therapy for patients with
candidemia or 4 mg/kg every 12 hours in patients with deep-tissue Candida
infections (disseminated infections of skin and infections of abdomen, kidney,
bladder wall, and wounds).
Minimum of 14 days following the resolution of symptoms or following the last
positive culture.
If the patient is unable to tolerate treatment, the dose may be reduced 3 mg/kg
every 12 hours.
Oral Esophageal candidiasis. Weight ≥40 kg (mL oral suspension):
- Loading dose: 400 mg (10 mL) every 12 hours (for the first 24 hours)
- Maintenance dose: 200 mg (5 mL) every 12 hours.
Weight ≤40 kg:
- Loading dose: 200 mg (5 mL) every 12 hours (for the first 24 hours)
- Maintenance dose: 100 mg (2.5 mL) every 12 hours.
Minimum of 7 days.
Abbreviations: FDA, US Food and Drug Administration.Therapeutics and Clinical Risk Management 2006:2(2) 132
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Interindividual variability in plasma voriconazole
concentrations is high, whereas intraindividual variation is
low. However, plasma levels increase disproportionately
with increasing doses, and steady-state levels are reached
after 5–7 days with 200 mg bid (Radford et al 1997). With
intravenous doses of 6 mg/kg bid, peak voriconazole plasma
levels consistently exceeded 3 mg/L in a child with invasive
aspergillosis, with trough levels maintained above 0.5 mg/
L (‘t Hek et al 1998).
Cerebral spinal fluid concentrations were 42%–67% of
the corresponding plasma levels at various times during
treatment (intravenous/oral) in one patient with cerebral
aspergillosis (Klasko 2005). In a single
nonimmunocompromised patient with fungal empyema, the
pleural fluid concentration of voriconazole was 64% of
serum levels when 200 mg bid was administered (Stern et
al 2004). Voriconazole has also been detected in the brain,
liver, kidney, heart, lung, and spleen at autopsy (Boucher et
al 2004).
Dose adjustments in special populations
Age
In clinical trials, median voriconazole plasma concentrations
in elderly patients (>65 years) were ~80%–90% higher than
those in younger patients. Although the manufacturer does
not recommend dose adjustments based on age, voriconazole
should be used with caution in elderly patients. There are
few pharmacokinetic studies in children, but the available
data suggest that voriconazole undergoes linear
pharmacokinetics in this population and that children may
have a higher capacity to eliminate voriconazole than adults
(Jeu et al 2003).
Renal insufficiency
Voriconazole AUC is not significantly different in patients
with moderate renal dysfunction (creatinine clearance 30–
50 mL/min). No dose adjustment of the oral formulation is
necessary in patients with renal insufficiency. However,
moderate renal insufficiency results in the accumulation of
Table 2 Comparative pharmacokinetic properties of triazoles (Sabo and Abdel-Rahman 2000; Jeu et al 2003; Boucher et al 2004;
Herbrecht 2004; Sadaba et al 2004; Klasko 2005)
Voriconazole Itraconazole Fluconazole
Cmax (mg/L) 0.9–2.5 0.2–1.1 2
tmax (h) 1–2 3–4 1–3
Oral: suggestive of saturable
first-pass metabolism.
AUC (µg × h/mL) Oral 19.86–50.32 Oral 22.6 Oral 10.5–15
Bioavailability (%) 90–96 55
a 93
Effects of food Cmax reduced by 34%. Capsules enhanced absorption. None
AUC reduced by 24%. Oral solution decreased
Tablets should be taken on an bioavailability,  so it should
empty stomach. not be administered with food.
Protein binding (%) 51–67 99 11–12
Vd (L/kg) 2–4.6 10–11 0.7–1.2
Metabolism Hepatic, by isoenzymes CYP2C19, Hepatic, by CYP isoenzymes. Hepatic, by CYP
CYP2C9, and CYP3A4, primarily via isoenzymes.
N-oxidation.
N-oxide metabolite inactive (72%).
Excretion Renal <2% UD and 80%–83% Renal <1% UD Renal 80% UD
metabolite form.
Bile primarily as metabolites.
t1/2 (h) 6 24 31
Hemodialysis Not dialyzable Not dialyzable Yes
A 4-hour hemodialysis session Hemodyalisis for 3 hours
does not remove a sufficient amount decreases plasma levels by
voriconazole to warrant dose approximately 50%.
adjustment.
Abbreviations: Cmax, maximum concentration; tmax, time to peak concentration (steady state); AUC, area under the curve; Vd, volume of distribution; t1/2, elimination
half-life; UD, unchanged drug.
Note: 
a Variability is a function of prandial state (capsule absorption is pH dependent) and oral formulation.Therapeutics and Clinical Risk Management 2006:2(2) 133
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the intravenous vehicle SBECD, which is renally excreted.
In a study of parenteral voriconazole in patients with
moderate renal dysfunction, the AUC and Cmax of SBECD
increased fourfold and by 50%, respectively, compared with
controls (Muijsers et al 2002). The intravenous vehicle of
voriconazole is a cyclodextrin. Consequently, in patients
with impaired renal function (creatinine clearance <50 mL/
min), assessment of the benefit/risk of administration by an
intravenous route is necessary (Johnson and Kauffman
2003).
Hepatic insufficiency
Dose adjustment is required for patients with chronic hepatic
impairment. For patients with Child–Pugh A and B cirrhosis,
it is recommended that the standard loading dose be given,
followed by half the daily maintenance dose. However, the
standard dose is recommended for patients with acute injury
resulting from graft-versus-host disease, sinusoidal
obstructive syndrome/veno-occlusive disease, or
hemodynamic hepatic injury (Johnson and Kauffman 2003;
Muijsers et al 2002).
Pregnancy
Voriconazole is teratogenic in animals and is listed as FDA
pregnancy category D (Pearson et al 2003).
Drug interactions
Voriconazole has many potential interactions because of its
extensive hepatic metabolism by CYP2C19, CYP2C9, and
CYP3A4. Drugs cleared through the CYP450 system may
interact with voriconazole, with complex effects on this
microsomal enzyme system exerted by either the target drug
or voriconazole. The metabolism of other drugs that are
substrates of this metabolic system may be inhibited by
voriconazole (Klasko 2005; Muijsers et al 2002; Pearson et
al 2003). Recommendations regarding voriconazole drug
interactions are shown in Table 3.
Side effects
Voriconazole is well tolerated. Three specific safety concerns
should be considered: adverse visual events, liver function
test abnormalities, and skin reactions.
Visual
Visual disturbances are the most frequent adverse events
associated with voriconazole. Transient altered perception
of light, photopsia, chromatopsia, photophobia, blurred
vision, or color vision changes have been observed in 8%–
44% of patients (Jeu et al 2003; Johnson and Kauffman
2003; Pearson et al 2003). The visual events begin 30
minutes after administration and last for about 30 minutes.
These side effects, associated with higher plasma
concentrations and/or doses of the drug, are mild and lead
to discontinuation in <1% of patients (Johnson and
Kauffman 2003; Pearson et al 2003). Abnormalities in
electroretinograms persist for the duration of treatment and
are completely reversed within two weeks of the
discontinuation of therapy (Boucher et al 2004).
Hepatic
Liver enzyme abnormalities (elevations of alkaline
phosphatase, glutamic-oxaloacetic transaminase (GOT)/
aspartate amino transferase (AST), or glutamic-pyruvic
transaminase (GPT)/amino alanine transferase (ALT) occur
in 12%–20% of patients treated with voriconazole. These
side effects usually normalize with continued administration
or upon discontinuation of voriconazole (4% to 8% of
patients), but serious events including hepatic failure and
death have been reported (Boucher et al 2004). Liver enzyme
abnormalities are a dose-limiting adverse effect and may
be associated with high voriconazole doses and/or serum
concentrations (Jeu et al 2003; Johnson and Kauffman 2003;
Pearson et al 2003).
Cutaneous
Skin rashes were reported in 19% of patients in clinical
studies of voriconazole. Most were mild and rarely led to
discontinuation. Several cases of severe skin reactions,
including Stevens–Johnson syndrome and toxic epidermal
necrolysis, were reported. Because photosensitivity
reactions have been described during voriconazole therapy,
patients should be advised to avoid sun exposure (Jeu et al
2003; Johnson and Kauffman 2003; Pearson et al 2003).
Miscellaneous
Other reported side effects of voriconazole include nausea
(5.9%), vomiting (4.8%), headache (3.2%), tachycardia
(2.5%), hypertension (1.9%), hypotension (1.7%),
abdominal pain (1.7%), and diarrhea (1.1%) (Klasko 2005).
In vitro studies
A large number of studies have been published reporting
the in vitro activity of voriconazole against yeasts, yeast-
like organisms, and moulds recovered from clinicalTherapeutics and Clinical Risk Management 2006:2(2) 134
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Table 3 Mechanisms of voriconazole drug interactions and recommendations for its use (Muijsers et al 2002; Venkataramanan et al
2002; Johnson and Kauffman 2003; Purkins et al 2003; Groll et al 2004; Klasko 2005)
Drug  Mechanism  Results/Drug plasma exposure Recommendation
Astemizole, Voriconazole inhibits ↑ plasma concentrations of Contraindicated.
terfenadine, CYP3A4 metabolism. astemizole. An increased risk of cardiotoxicity
quinidine, dofetilide (QT prolongation, torsade de pointes, cardiac
arrest).
Azithromycin Azithromycin inhibits ↑ voriconazole Cmax (8%) and No adjustment of voriconazole dose.
CYP450 metabolism of AUC (1%).
voriconazole (unclear).
Barbiturates Barbiturates inhibit CYP450 Systemic exposure to voriconazole Contraindicated.
metabolism of voriconazole.  significantly reduced.
Benzodiazepines Voriconazole inhibits CYP3A4 ↑ plasma exposure. Frequent monitoring for adverse events and
metabolism. toxicity (prolonged sedation). Dose adjustment of
benzodiazepine may be necessary.
Calcium channel Voriconazole inhibits CYP3A4 ↑ plasma concentrations of calcium Frequent monitoring for adverse events and
blockers metabolism.  channel blockers. toxicity.  Dose adjustment of calcium channel
blockers.
Carbamazepine Carbamazepine inhibits ↓ systemic exposure of voriconazole. Contraindicated.
CYP450 metabolism.
Cyclosporine Voriconazole inhibits ↑ AUC cyclosporine ~70% ↓ cyclosporine dose by 50%. Monitor
CYP3A4 metabolism. ↑ cyclosporine trough levels by 2.5. cyclosporine levels and signs of toxicity.
Digoxin Voriconazole inhibits CYP3A4 ↑ digoxin Cmax (10%) and AUC (1%). No dose adjustment recommended.
metabolism.
Ergot alkaloids Voriconazole inhibits CYP. Likely to be increased (based on Contraindicated.
available data; not studied).
Erythromycin Erythromycin and ↑ plasma concentrations of No adjustment of voriconazole dose.
voriconazole inhibit their voriconazole (Cmax 8% and AUC 1%) Monitor patients for signs.
CYP3A4 metabolism.  and erythromycin.
HMG–CoA Voriconazole inhibits ↑ plasma exposure of HMG–CoA Frequent monitoring for adverse events and
reductase inhibitors CYP3A4 metabolism. reductase inhibitors (in vitro  toxicity related to statins. Increased statin
(statins) studies). concentrations in plasma have been associated
with rhabdomyolysis.  Adjustment of the statin
dose may be necessary.
Imatinib Voriconazole inhibits ↑ plasma exposure of imatinib. Monitor for signs of imatinib dose-related adverse
CYP3A4 metabolism. events (fluid retention/water gain, nausea and
vomiting, neutropenia).
Indinavir Indinavir inhibits CYP450 ↑ voriconazole Cmax (2%) and  No dose adjustment required for indinavir.
HIV protease metabolism of voriconazole. AUC (7%). Frequent monitoring for adverse events related
inhibitors Voriconazole inhibits ↑ voriconazole exposure. to other HIV protease inhibitors.
CYP3A4 metabolism of ↑ indinavir Cmax (9%) and AUC
indinavir. (11%).
NNRTIs Voriconazole inhibits CYP3A4 ↑ plasma exposure (in vitro studies). Frequent monitoring for adverse events and
metabolism. toxicity related to NNRTIs.
Omeprazole Competitive inhibition of ↑ voriconazole Cmax (15%) and Reduce omeprazole dose by 50% when starting
omeprazole and voriconazole AUC (41%). voriconazole. No change in voriconazole dose.
metabolim by CYP2C19 ↑ omeprazole Cmax (3.8-fold)
and CYP3A4.  and AUC (2.2-fold).
↑ exposure to voriconazole
and omeprazole.  
Phenytoin Voriconazole inhibits ↑ phenytoin Cmax (67%) and AUC Monitor phenytoin levels and phenytoin-related
CYP2C9 metabolism of (81%). adverse events. Adjust voriconazole dose to
phenytoin. ↓ voriconazole Cmax (51%) and 5 mg/kg intravenously or to 400 mg orally, twice
Phenytoin induces CYP3A4 AUC (31%). daily.
metabolism of voriconazole.
Prednisolone Competitive inhibition of - prednisolone Cmax (11%) and No dose adjustment required.
CYP3A4. AUC (34%).  Slight accumulation
of voriconazole.Therapeutics and Clinical Risk Management 2006:2(2) 135
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specimens. The majority of authors have evaluated the in
vitro activity of voriconazole with reference to the method
of the Clinical Laboratory Standards Institute (CLSI)
(formerly the National Committee for Clinical Laboratory
Standards [NCCLS]) M27-A2 or European Committee on
Antimicrobial Susceptibility Testing (EUCAST) methods
for yeasts, and M38-A for moulds. Other studies have used
marketed methods such as Sensititre YeastOne
® (TREK
Diagnostic Systems Ltd., West Sussex, England) and Etest
®
(AB BIODISK, Solna, Sweden) to determine the in vitro
susceptibility to voriconazole of pathogenic fungi. The
correlation between the results obtained by those methods
and those obtained with the CLSI methods is >90% for both
yeasts and filamentous fungi (Espinel-Ingroff and Rezusta
2002; Espinel-Ingroff et al 2004; Serrano et al 2004; Linares,
Charriel, et al 2005). Tentative interpretive breakpoints for
voriconazole have recently been established by the CLSI
(Minutes of CLSI Antifungal Subcommittee Meeting, 2005),
in which a strain is categorized as “susceptible” if the
minimal inhibitory concentration (MIC) is ≤1 µg/mL,
“susceptible dose-dependent” if the MIC = 2 µg/mL, and
“resistant” if the MIC is ≥4 µg/mL (Espinel-Ingroff et al
2005; Pfaller, Boyken, et al 2005).
The in vitro activity of voriconazole has been reviewed
in published studies, examining a total of 25 470 clinical
isolates of yeasts, 104 algae, and 3216 filamentous fungi
(Tables 4 and 5).
In vitro activity against yeasts and algae
A review of in vitro voriconazole activity against yeasts
includes 25 470 clinical isolates belonging to 15 genera and
60 different species (Table 4). Voriconazole has shown
activity against Candida spp, including fluconazole-resistant
isolates and those species intrinsically resistant to
fluconazole (C. krusei, C. norvegensis, and C. inconspicua).
Its in vitro activity against Cryptococcus spp is superior to
that of flucytosine and fluconazole: 92% of isolates are
susceptible to voriconazole (MIC≤1 µg/mL) versus 44%
susceptible to flucytosine (MIC≤4 µg/mL) and 83% to
fluconazole (MIC≤8µg/mL) (Pfaller, Messer, et al 2005).
Moreover, voriconazole has in vitro activity against
emerging yeast-like pathogens such as Rhodotorula spp (a
microorganism resistant to fluconazole and caspofungin)
(Diekema et al 2005) and Blastoschizomyces capitatus
(formerly Geotricum capitatum). Data on the in vitro
susceptibility to antifungal agents of B. capitatus are scarce,
although decreased susceptibility to fluconazole and
flucytosine have been reported, and high levels of
susceptibility to voriconazole (MIC range, 0.03–0.5 µg/mL)
(Girmenia et al 2003). The in vitro activity of voriconazole
Rifabutin Rifabutin induces CYP450 ↓ voriconazole Cmax (66%) and Contraindicated.
metabolism of voriconazole. AUC (79%) If benefits of co-administration outweigh risks,
Voriconazole inhibits CYP3A4 ↓ rifabutin Cmax (69%) and adjust voriconazole dose to 5 mg/kg intravenously
metabolism of rifabutin. AUC (78%). or to 400 mg orally, twice daily.
Rifampin Rifampin induces CYP450 ↓ voriconazole Cmax (92%) and Contraindicated.
metabolism of voriconazole. AUC (96%).
Sirolimus Voriconazole inhibits ↑ plasma concentrations of sirolimus. Contraindicated.
CYP3A4 metabolism.  
Sulfonylureas Voriconazole inhibits ↑ plasma concentrations of Frequent monitoring of blood glucose and
(tolbutamida, CYP3A4 metabolism. sulfonylureas. appropriate adjustment of the sulfonylurea dose.
glipizide, glyburide)
Tacrolimus Voriconazole inhibits ↑ tacrolimus Cmax (2.2-fold) and Reduce tacrolimus dose by a third when starting
CYP3A4 metabolism AUC (3.2-fold). voriconazole.
(dose dependent). Monitor plasma levels frequently.
Vinca alkaloids Voriconazole inhibits ↑ plasma concentrations of Dose adjustment of vinca alkaloids.
(vincristine, CYP3A4 metabolism. vinca alkaloids.
vinblastine,
vinorelbine)
Warfarin oral Voriconazole inhibits ↑ warfarin effect Monitor prothrombin time.
anticoagulants CYP3A4 metabolism. (↑ prothrombin time). Adjust warfarin dose if necessary.
Increased risk of bleeding.
Abbreviations: NNRTIs, nonnucleoside reverse transcriptase inhibitor; AUC, area under the curve; Cmax, maximum concentration; CY, cytochrome.
Table 3 Continued
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Table 4 In vitro activity of voriconazole against 25 470 strains of yeasts and 104 strains of algae
Genus and species
(No. strains reviewed) MIC MIC50 MIC90
Arxiozyma (6)
A. telluris FZ-R 0.03–0.5  0.12 Cuenca-Estrella et al 2004 
Blastoschizomyces (46)
B. capitatus 0.03–0.5   0.25 Girmenia et al 2003
B. capitatus FZ-R 0.06–2  0.34
a Cuenca-Estrella et al 2004
B. capitatus FZ-S 0.015–0.25   0.1a
        
Candida (22 701)       
C. albicans (9715) 0.008–>16 0.008–0.5 0.015–2 Chavez et al 1999; Chryssanthou and Cuenca-Estrella 2002;
Cuenca-Estrella et al 2005; Girmenia et al 2000; Linares et al 2004;
Marco et al 2003; Ostrosky-Zeichner, Rex, et al 2003; Pelletier et al
2002; Pemán et al 2005; Pfaller, Jones, et al 1999a; Pfaller et al 2002b;
Pfaller, Espinel-Ingroff, et al 2004; Pfaller, Messer, et al 2004; Rubio et al
2003; Takakura et al 2004; Uzun et al 2000;  Vazquez et al 1997;
Yang et al 2004
C. albicans (FZ-R) 0.03–16  0.44
a Cuenca-Estrella et al 2004
C. albicans (FZ-S) 0.01–1  0.01a
C. ciferrii (6) 0.12–0.5 0.25   Espinel-Ingroff et al 2001 
C. dubliniensis (344) <0.008–>8 <0.008– 0.015– Maxwell et al 2003; Ostrosky-Zeichner, Rex, et al 2003; Pfaller, Messer,
0.125  0.125 et al 1999a; Pfaller et al 2002b; Pfaller et al 2003; Pfaller and Diekema
2004; Quindós et al 2000; Rubio et al 2003
C. dubliniensis FZ-R 0.25  0.01
a Cuenca-Estrella et al 2004
C. dubliniensis FZ-S 0.01  0.25a
C. famata (22) 0.008–1   <0.03 Espinel-Ingroff et al 2001; Maxwell et al 2003; Pfaller et al 2003; Rubio
–0.5 et al 2003
C. glabrata (5400) <0.008–>16 0.06–0.5 0.25–4 Barchiesi et al 2004; Burn et al 2004; Chavez et al 1999; Chryssanthou
and Cuenca-Estrella 2002; Cuenca-Estrella et al 2005; Drago et al 2004;
Linares et al 2004; Marco et al 2003; Ostrosky-Zeichner, Rex, et al
 2003; Pai and Jones 2004; Pelletier et al 2002; Pemán et al 2005;
Pfaller, Jones, et al 1999a; Pfaller et al 2002b; Pfaller, Espinel-Ingroff, et al
2004; 2004a; Pfaller, Messer, et al 2004; Rubio et al 2003; Swinne et al
2004; Swinne et al 2005; Takakura et al 2004;Tortorano et al 2003;
Uzun et al 2000; Vazquez et al 1997;  Yang et al 2004
C. glabrata FZ-R 0.06–16   0.72
a Cuenca-Estrella et al 2004
C. glabrata FZ-S 0.01–1  0.17a
C. guilliermondii (351) 0.007–>16 0.06–0.125  0.12–0.5 Chryssanthou and Cuenca-Estrella 2002; Maxwell et al 2003; Ostrosky-
Zeichner, Rex, et al 2003; Pfaller et al 2002b; Pfaller et al 2003; Pfaller
and Diekema 2004; Rubio et al 2003; Tortorano et al 2003
C. guilliermondii FZ-R 0.03–2  0.22a Cuenca-Estrella et al 2004
C. guilliermondii FZ-S 0.01–0.25  0.07
a
C. haemulonii FZ-R 8–16  12
a
C. haemulonii FZ-S 0.12  0.12
a
C. inconspicua (6) 0.25–4     Pfaller et al 2003 
C. inconspicua FZ-R 0.01     Cuenca-Estrella et al 2004
C. inconspicua FZ-S 0.015–0.12     Cuenca-Estrella et al 2004; Maxwell et al 2003
C. kefyr (56) 0.008–0.125  0.015 0.03–0.06 Espinel-Ingroff et al 2001; Maxwell et al 2003; Ostrosky-Zeichner, Rex,
et al 2003; Pfaller et al 2003; Uzun et al 2000 
C. krusei (1,337) <0.008–4 0.06–0.5  0.25–2 Chavez et al 1999; Chryssanthou and Cuenca-Estrella 2002; Cuenca-
Estrella et al 2004; Cuenca-Estrella et al 2005; Drago et al 2004;
Linares et al 2004; Marco et al 2003; Maxwell et al 2003; Ostrosky-
Zeichner, Rex, et al 2003; Pelletier et al 2002; Pemán et al 2005;
Pfaller et al 2002b; Pfaller et al 2003; Pfaller, Espinel-Ingroff, et al 2004;
Pfaller and Diekema 2004; Pfaller, Messer, et al 2004; Rubio et al 2003;
Swinne et al 2004; Swinne et al 2005; Takakura et al 2004; Tortorano
et al 2003; Uzun et al 2000; Vazquez et al 1997; Yang et al 2004
C. lambica (8) <0.03–0.5  <0.03   Espinel-Ingroff et al 2001; Pfaller et al 2003 Therapeutics and Clinical Risk Management 2006:2(2) 137
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Table 4 Continued
Genus and species
(No. strains reviewed) MIC MIC50 MIC90
C. lipolytica (24) 0.015–4  0.06 0.015–4 Espinel-Ingroff et al 2001; Maxwell et al 2003; Ostrosky-Zeichner,
Rex, et al 2003; Pelletier et al 2002; Pfaller et al 2003;
Tortorano et al 2003
C. lusitaniae (582) 0.008–4 0.008–0.03 0.016–0.5 Chryssanthou and Cuenca-Estrella 2002; Favel et al 2004; Linares et al
2004; Maxwell et al 2003; Ostrosky-Zeichner, Rex, et al 2003;
Pelletier et al 2002; Pfaller et al 2002b; Pfaller et al 2003; Pfaller,
Espinel-Ingroff, et al 2004; Pfallerand Diekema 2004; Pfaller, Messer, et
al 2004; Rubio et al 2003; Swinne et al 2004; Swinne et al 2005;
Tortorano et al 2003
C. lusitaniae FZ-R 0.12   0.12 Cuenca-Estrella et al 2004
C. lusitaniae FZ-S 0.01–0.03  0.01
a
C. norvegensis (2) 0.12     Maxwell et al 2003; Pfaller et al 2003 
C. parapsilosis (2703)  0.008–8 0.008–0.06 0.015–4 Chavez et al 1999; Chryssanthou and Cuenca-Estrella 2002;
Cuenca-Estrella et al 2005; Linares et al 2004; Marco et al 2003;
Ostrosky-Zeichner, Rex, et al 2003; Pelletier et al 2002; Pemán et al
2005; Pfaller, Jones, et al 1999a; Pfaller et al 2002b; Pfaller, Espinel-
Ingroff, et al 2004; Pfaller, Messer, et al 2004; Rubio et al 2003;
Swinne et al 2004; Swinne et al 2005; Takakura et al 2004; Tortorano et
al 2003; Uzun et al 2000; Vazquez et al 1997; Yang et al 2004
C. parapsilosis FZ-R 0.12–0.5   0.25
a Cuenca-Estrella et al 2004 
C. parapsilosis FZ-S 0.01–0.12  0.02a
C. pelliculosa (38) 0.06–0.5  0.12 0.25–0.5 Maxwell et al 2003; Pfaller et al 2003; Pfaller, Messer, et al 2004;
Tortorano et al 2003
C. rugosa (52) 0.008–0.25 0.06 0.12–0.25 Espinel-Ingroff et al 2001; Maxwell et al 2003; Ostrosky-Zeichner,
Rex, et al 2003; Pfaller et al 2003; Pfaller and Diekema 2004
C. rugosa FZ-R 0.25  0.25
a Cuenca-Estrella et al 2004
C. rugosa FZ-S 0.01–0.25  0.06a
C. sake (3) 0.015–8   0.5 Pelletier et al 2002; Pfaller et al 2003
C. sphoerica (1)  0.03     Ostrosky-Zeichner, Rex, et al 2003
C. stellatoidea (1) 0.125     Espinel-Ingroff et al 2001
C. tropicalis (1850) 0.008–>16 0.03–0.5 0.03–>16 Chavez et al 1999; Chryssanthou and Cuenca-Estrella 2002; Cuenca-
Estrella et al 2005; Linares et al 2004; Marco et al 2003; Ostrosky-
Zeichner, Rex, et al 2003; Pelletier et al 2002; Pemán et al 2005; Pfaller,
Jones, et al 1999a; Pfaller et al 2002b; Pfaller, Espinel-Ingroff, et al 2004;
Pfaller, Messer, et al 2004; Rubio et al 2003; Swinne et al 2004; Swinne
et al 2005; Takakura et al 2004; Tortorano et al 2003; Uzun et al 2000;
Vazquez et al 1997; Yang et al 2004
C. tropicalis FZ-R 0.01–16  0.84
a Cuenca-Estrella et al 2004
C. tropicalis FZ-S 0.01–4  0.03a
C. zeylanoides FZ-R  0.12–0.25   0.18
a Cuenca-Estrella et al 2004 
C. zeylanoides FZ-S 0.008–0.25     Maxwell et al 2003; Pfaller et al 2003
Candida spp (188) 0.008–2 0.03–0.25 0.025–2 Chryssanthou and Cuenca-Estrella 2002; Cuenca-Estrella et al 2004;
Marco et al 2003; Pfaller, Jones, et al 1999a; Rubio et al 2003; Cuenca-
Estrella et al 2005; Pfaller, Espinel-Ingroff, et al 2004; Takakura et al
2004
Cryptococcus (2368)       
C. albidus FZ-R 0.25–4  0.79
a Cuenca-Estrella et al 2004
C. albidus FZ-S 0.25   
C. gatii FZ-R 0.25–1  0.62
a
C. gatii FZ-S 0.03–0.12  0.08a
C. laurentii FZ-R 0.25–8  1.25
a
C. laurentii FZ-S 0.06–0.5  0.12
a
C. neoformans (2349) 0.008–4 0.12–0.25 Pfaller, Messer, et al 2004; Pfaller, Messer, et al 2005
C. neoformans-Africa (52) 0.004–0.5 0.125 Chandenier et al 2004
C. neoformans-Asia (110) 0.012–>32  
C. neoformans FZ-R 0.03–4 0.24
a Cuenca-Estrella et al 2004Therapeutics and Clinical Risk Management 2006:2(2) 138
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Table 4 Continued
Genus and species
(No. strains reviewed) MIC MIC50 MIC90
C. neoformans FZ-S 0.01–0.5 0.11
a
Debaryomyces (15)       
D. hansenii FZ-R 0.016–8  0.31a Cuenca-Estrella et al 2004
D. hansenii FZ-S 0.016–0.12  0.03
a  
Geotrichum (9)       
G. candidum FZ-R 0.5–4  1.22
a Cuenca-Estrella et al 2004
G. candidum FZ-S 0.03–0.25   0.08
a
Hansenula (5)       
H. anomala  0.12–0.25 0.25 0.25a Espinel-Ingroff et al 2001
Malassezia (70)       
M. furfur (24) <0.03–0.12   0.06 Garau et al 2003 
M. pachydermatis (10) <0.03–0.12  0.06
M. sloffiae (15) <0.03   <0.03
M. sympodialis (21) <0.03  <0.03
Pichia (9)       
P. anomala FZ-R  0.12     Cuenca-Estrella et al 2004
P. anomala FZ-S 0.06    
P. membranifaciens FZ-R  0.016–0.25  0.09a
P. norvegensis FZ-R  0.25–0.5  0.35a
P. norvegensis FZ-S 0.01   
Rhodotorula (84)       
R. glutinis (31) <0.06–4   8 Diekema et al 2005
R. glutinis FZ-R 0.25–0.5  0.37
a Cuenca-Estrella et al 2004
R. mucilaginosa (rubra) (53) <0.06–6 4 8 Diekema et al 2005; Espinel-Ingroff et al 2001 
R. mucilaginosa FZ-R 0.25–8  2.7
a Cuenca-Estrella et al 2004 
Saccharomyces (15)        
S. cerevisiae  0.06–0.25 0.12   Espinel-Ingroff et al 2001
S. cerevisiae FZ-R 0.25–2  0.79a Cuenca-Estrella et al 2004
S. cerevisiae FZ-S 0.06–0.12  0.07
a
Sporobolomyces (3)       
S. salmonicolor 0.25–4     Espinel-Ingroff et al 2001
Torulospora (3)       
T. delbrueckii FZ-R 4  4a Cuenca-Estrella et al 2004
T. delbrueckii FZ-S 0.06–0.12  0.08a
Trichosporon (134)        
T. asahii (beigelii) (69) <0.03–1  0.06 0.16
a Espinel-Ingroff et al 2001; McGinnis et al 1998; Paphitou et al 2002 
T. asahii FZ-R 0.25–8  3.36a Cuenca-Estrella et al 2004
T. asahii FZ-S 0.06–1  0.1
a
T. asteroides  <0.03–0.06     McGinnis et al 1998
T. brassicae 0.06   
T. coremiforme 0.06   
T. cutaneum FZ-R 8     Cuenca-Estrella et al 2004; McGinnis et al 1998
T. cutaneum FZ-S 0.01–0.12  0.06a
T. dulcitum  0.25–1  0.5
a McGinnis et al 1998; Paphitou et al 2002
T. faecalie 0.12   
T. gracile  0.12   
T. inkin  0.06   
T. laibachii  <0.03   
T. loubieri  0.12   
T. montevideense 8  
T. mucoides FZ-R 0.03–8  1.2
a Cuenca-Estrella et al 2004
T. mucoides FZ-S & SDD 0.125–0.5   0.25a McGinnis et al 1998
T. mucoides FZ-S 0.01-0.25  0.09
a Cuenca-Estrella et al 2004
T. ovoides FZ-S 0.06   McGinnis et al 1998
T. non-asahii    16 McGinnis et al 1998; Paphitou et al 2002
T. pullulans  1  
T. sporotrichoides                    0.06   Therapeutics and Clinical Risk Management 2006:2(2) 139
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against Trichosporon depends on the species: among all the
species assayed (Table 4), high voriconazole MIC values
(≥4 µg/mL) were found for some T. asahii and T. mucoides
isolates (Pfaller and Diekema 2004; Rodriguez-Tudela et al
2005).
The susceptibility to voriconazole of fluconazole-
resistant isolates depends on the phenotype. Isolates with
the fluconazole-resistant and itraconazole-susceptible
phenotype (RS) are susceptible to voriconazole and those
with the fluconazole- and itraconazole-resistant phenotype
(RR) are resistant to voriconazole.
Nearly all in vitro studies of voriconazole recorded
high MICs (≥4 µg/mL) for the species C. albicans, C.
glabrata, and C. tropicalis, and for some of the emerging
species of Candida (Table 4), although the majority of
authors reported very low MIC90 values for C. albicans
(≤0.06 µg/mL). It is difficult to determine the percentage
of voriconazole-resistant isolates for each species because
published data refer to the range and MIC90 or the
percentage of isolates inhibited by ≤1 µg/mL. An in vitro
study of 6 972 invasive clinical Candida spp isolates from
more than 200 centers worldwide (Pfaller et al 2002b)
reported an overall resistance to voriconazole of 1%, and
among the fluconazole-resistant isolates, 71% were
susceptible to voriconazole.
Prototheca wickerhamii is the causal agent of cutaneous
and subcutaneous infections and, in rare cases, systemic
disease. The in vitro activity of voriconazole against this
intrinsically fluconazole-resistant alga has recently been
reported. All 104 isolates assayed were inhibited by ≤0.5 µg/
mL voriconazole (Linares, Solis, et al 2005).
Cross-resistance among triazoles has been reported only
for the RR phenotype. Notably, voriconazole is active
against both the RR and RS phenotypes of C. krusei (Pfaller
et al 2002b), suggesting that the mechanisms of resistance
to azoles are different in this species from those of other
Candida spp.
Fungicidal activity of voriconazole
Partial growth inhibition or “trailing” has been reported
for C. albicans and C. tropicalis isolates, whereas
voriconazole produces complete inhibition of growth in
other species. The minimum fungicidal concentration
(MFC) of voriconazole has been determined for these
strains and also for C. albicans and C. tropicalis isolates
that have no trailing growth. In the first report of
voriconazole fungicidal activity against Candida spp, the
MFC ranged from 0.03 µg/mL to 2 µg/mL for C. krusei,
C. parapsilosis, C. dubliniensis, C. lusitaniae, C.
albicans, and C. tropicalis; the MFC values were ≥4 µg/
mL against only C. glabrata and C. dubliniensis (Rubio
et al 2005). Moreover, the fungicidal activity of
voriconazole against 10% of non-C. albicans species and
40% of C. parapsilosis has been observed (Ghannoum
et al 2005). Other authors have reported voriconazole
fungicidal activity to be ≥8 µg/mL against Trichosporon
spp (Paphitou et al 2002) and C. neoformans (van Duin
et al 2004). In contrast, voriconazole fungicidal activity
has not been demonstrated with killing curves except for
C. neoformans (Manavathu et al 1998; Ernst et al 2002).
In vitro activity against filamentous fungi
The activity of voriconazole against filamentous fungi has
been studied for dimorphic, basidiomycetes, dematiaceus,
dermatophytes, zygomycetes, and hyphomycetes moulds
(Table 5). In total, the activity of voriconazole against 3 216
filamentous fungi has been reviewed. Many of the mould
species evaluated in the in vitro susceptibility studies are
uncommon causes of human infections, and the number of
isolates tested has been limited.
Voriconazole is active against a wide range of
dematiaceus moulds, including those that cause
eumycetoma, such as Leptosphaeria senegalensis and
Madurella mycetomatis. Among the 30 genera tested by
Table 4 Continued
Genus and species
(No. strains reviewed) MIC MIC50 MIC90
Yarrowia (8)
Y. lipolytica FZ-R  0.12–2 0.59
a Cuenca-Estrella et al 2004
Y. lipolytica FZ-S  0.01–0.25 0.05
a
Algae (104)
Prototheca wickerhamii <0.008–0.5    0.12 0.5 Linares, Solis, et al 2005
a Geometric mean.  Voriconazole activity has been separated according to fluconazole susceptibility when authors presented it in that way.
Abbreviations: FZ-R, fluconazole-resistant (MIC ≥ 64 µg/mL); FZ-SDD, fluconazole susceptible-dose dependent (MIC = 16–32 µg/mL); FZ-S, fluconazole-susceptible
(MIC≤8 µg/mL); MIC, range of minimal inhibitory concentrations (µg/mL); MIC50 and MIC90, range of minimal inhibitory concentration at which 50% and 90% of
isolates are inhibited, respectively.Therapeutics and Clinical Risk Management 2006:2(2) 140
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Table 5 In vitro activity of voriconazole against 3216 strains of filamentous fungi
Genus and species (No. tested) MIC/MFC MIC90 Reference
Basidiomycetes (44)
Bjerkandera adusta (14) 0.25–0.5 0.5 Gonzalez et al 2001
Coprinus spp (8) 0.25–0.5 0.5 Gonzalez et al 2001
Schizophyllum commune (5) 0.5–1 0.5 Gonzalez et al 2001
Unidentified (17) 0.5–1 0.5 Gonzalez et al 2001
Dematiaceus (536)
Alternaria alternata (5) 0.5–1 0.63
b Espinel-Ingroff et al 2001; Radford et al 1997
Alternaria spp (4) 1–2 1.25
b Espinel-Ingroff et al 2001l
Aurebasidium pullulans (5) 0.03–0.25 0.14
b Espinel-Ingroff et al 2001
Bipolaris australiensis (6) 0.125–2 0.2
b Espinel-Ingroff et al 2001; Radford et al 1997
Bipolaris hawaiiensis (23) 0.06–0.5 0.15–0.5
b Espinel-Ingroff et al 2001
Bipolaris specifera (32) 0.06–2 0.29–2
b Espinel-Ingroff et al 2001
Bipolaris spp (16) 0.12–1 0.33
b Espinel-Ingroff 1998
Botryomyces caespitosus (1) 2 Espinel-Ingroff et al 2001
Chaetomium globosum (4) 0.125–0.5 0.21
b Espinel-Ingroff et al 2001
Cladophialophora carrionii (22) 0.03–0.125 0.05
b Espinel-Ingroff et al 2001
Cladophialophora bantiana (44) <0.03–1 0.12–0.5 Espinel-Ingroff et al 2001; Radford et al 1997
Cladosporium cladosporioides (3) 0.06–1 0.08
b Espinel-Ingroff et al 2001
Cladosporium sphaerospermum (5) 0.5–1 0.87b Espinel-Ingroff et al 2001
Coniothyrium fuckelii (5) 0.125–0.5 0.22
b Espinel-Ingroff et al 2001
Curvularia inaequalis (1) 0.25 Espinel-Ingroff et al 2001
Curvularia lunata (22) 0.06–1 0.22
b Espinel-Ingroff et al 2001; Radford et al 1997
Curvularia senegalensis (3) 0.06–00.25 0.2
b Espinel-Ingroff et al 2001
Curvularia verruculosa (3) 0.125 Espinel-Ingroff et al 2001
Dactylaria constricta (21) 0.03–1/0.5–>8 0.12–0.5 Espinel-Ingroff et al 2001
Dissitumurus exedrus (1) 0.25 Espinel-Ingroff et al 2001
Drechslera biseptata (1) 0.06 Espinel-Ingroff et al 2001
Exophiala jeanselmei (36) <0.03–8 0.6
b Espinel-Ingroff et al 2001; Radford et al 1997
Exophiala moniliae (3) 0.25–0.5 0.32
b Espinel-Ingroff et al 2001
Exophiala pisciphila (4) 0.25–1 0.59
b Espinel-Ingroff et al 2001
Exophiala spinifera (10) 0.125–1 0.2b Espinel-Ingroff et al 2001
Exserohilum rostratum (12) 0.06–0.5 0.17
b Espinel-Ingroff et al 2001
Fonsecaea compacta (8) <0.03–0.5 0.14
b Espinel-Ingroff et al 2001; Radford et al 1997
Fonsecaea pedrosoi (36) <0.03–1/<0.03–1 0.06 Espinel-Ingroff et al 2001; Radford et al 1997
Hormonema dematioides (3) 0.06–032 0.23
b Espinel-Ingroff et al 2001
Hortaea spp (11) 0.03–0.125 0.05
b Espinel-Ingroff et al 2001
Lasiodiploidia theobromae (2) 1 Radford et al 1997
Lecythophora hoffmanii (5) 0.125–0.5 0.29
b Espinel-Ingroff et al 2001
Lecythophora mutabilis (6) 0.125–0.5 0.22
b Espinel-Ingroff et al 2001; Radford et al 1997
Leptosphaeria senegalensis (2) <0.03–0.06 Radford et al 1997
Madurella grisea (1) 0.5 Espinel-Ingroff et al 2001
Madurella mycetomatis (8) 0.03–0.5 0.05
b Espinel-Ingroff et al 2001; Radford et al 1997
Phaeoacremonium parasiticum (18) 0.125–2/0.25–1 0.25b Espinel-Ingroff et al 2001
Phaeoannellomyces elegans (4) 0.06–8 0.5b Espinel-Ingroff et al 2001
Phaeosclera dematioides (1) 4 Espinel-Ingroff et al 2001
Phialemonium curvatum (3) 0.25 Espinel-Ingroff et al 2001
Phialemonium obovatum (5) 0.25–1 0.5b Espinel-Ingroff et al 2001
Phialophora americana (3) 0.125 Espinel-Ingroff et al 2001
Phialophora fastigiata (1) 1 Espinel-Ingroff et al 2001
Phialophora repens (3) 0.25 Espinel-Ingroff et al 2001
Phialophora richardsiae (11) 0.25–2 0.64
b Espinel-Ingroff et al 2001
Phialophora verrucosa (25) 0.03–0.5 0.12b Espinel-Ingroff et al 2001
Ramichloridium mackenziei (4) 0.06 Radford et al 1997
Rhinocladiella aquaspersa (2) 0.03–0.25 0.09
b Espinel-Ingroff et al 2001
Rhinocladiella atrovirens (3) 0.03–0.5 0.18b Espinel-Ingroff et al 2001
Scolecobasidium constrictum (5) 0.03–8 0.43b Espinel-Ingroff et al 2001
Scolecobasidium humicola (4) 0.03–4 0.21
b Espinel-Ingroff et al 2001
Scytalidium dimidiatum (24) <0.03–0.5 0.1
b Espinel-Ingroff et al 2001; Lacroix and Feuilhade 2005Therapeutics and Clinical Risk Management 2006:2(2) 141
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Scytalidium hyalinum (15) <0.002–0.006 Lacroix and Feuilhade 2005
Wangiella dermatiditis (31) 0.03–0.5/0.06–1 0.12 Espinel-Ingroff et al 2001; Radford et al 1997
Dermatophytes (120)
Microsporum canis (34) 0.06–2 0.12 Serrano-Martino et al 2003
Microsporum gypseum (13) 0.12–1 0.5 Serrano-Martino et al 2003
Trichophyton mentagrophytes (61) 0.06–1 0.5 Serrano-Martino et al 2003
Trichophyton rubrum (12) 0.06–2 0.25 Serrano-Martino et al 2003
Dimorphic (532)
Blastomyces dermatitidis (142) <0.03–16/<0.03–32 0.25 Espinel-Ingroff et al 2001
Coccidioides immitis (142) <0.03–0.5/>32 0.25 Espinel-Ingroff et al 2001
Histoplasma capsulatum (144) <0.03–2/<0.03–>32 0.25 Espinel-Ingroff et al 2001
Paracoccidioides brasiliensis (19) <0.03–2 Espinel-Ingroff et al 2001
Penicillium marneffei (34) <0.03 Espinel-Ingroff et al 2001; Radford et al 1997
Sporothrix schenckii (51) 0.12–>16/0.5–>16 >16 Espinel-Ingroff et al 2001; Radford et al 1997
Hyphomycetes (1,922)
Acremonium alabamense (1) 0.25 Espinel-Ingroff et al 2001
Acremonium kiliense (2) 1 Radford et 1997
Acremonium spp (1) 0.25 Marco et al 1998
Acremonium strictum (1) 2 Espinel-Ingroff et al 2001
Aspergillus flavipes (2) 0.03–0.12 Serrano et al 2003
Aspergillus flavus (218) <0.03–2/0.25–8 0.06–1 Diekema et al 2003; Espinel-Ingroff et al 2001; Espinel-Ingroff
and Rezusta 2002; Hsueh et al 2005; Maesaki et al 2000; Marco
et al 1998; Pfaller et al 2002a; Serrano et al 2003
Aspergillus fumigatus (802) <0.03–8/0.25–>8 0.25–1 Clancy and Nguyen 1998; Cuenca-Estrella et al 1998; Diekema
et al 2003; Espinel-Ingroff et al 2001; Espinel-Ingroff and Rezusta
2002; Hsueh et al 2005; Maesaki et al 2000; Marco et al 1998;
Pfaller et al 2002a; Serrano et al 2003
Aspergillus glaucus (8) 0.06–0.12 0.06 Serrano et al 2003
Aspergillus nidulans (26) 0.03–4/0.12–4 0.5 Espinel-Ingroff et al 2001; Espinel-Ingroff and Rezusta 2002
Aspergillus niger (141) <0.03–4/0.25–2 0.12–2 Diekema et al 2003; Espinel-Ingroff et al 2001; Espinel-Ingroff
and Rezusta 2002; Hsueh et al 2005; Maesaki et al 2000; Marco
 et al 1998; Pfaller et al 2002a; Serrano et al 2003
Aspergillus terreus (188) <0.03–2/1–16 0.25–1 Diekema et al 2003; Espinel-Ingroff et al 2001; Espinel-Ingroff
and Rezusta 2002; Hsueh et al 2005; Marco et al 1998; Pfaller et
al 2002a; Serrano et al 2003
Aspergillus ustus (12) 0.25–8/0.25–32 8 Espinel-Ingroff et al 2001
Aspergillus versicolor (29) 0.06–2 1 Diekema et al 2003; Pfaller et al 2002a
Aspergillus spp (32) 0.12–>8 1 Pfaller et al 2002a
Fusarium moniliforme (9) 0.5–>8/4–>8 2 Espinel-Ingroff et al 2001
Fusarium oxysporum (33) 0.25–>8/2–>16 8 Espinel-Ingroff et al 2001; Minassian et al 2003; Radford et al 1997
Fusarium proliferatum (6) 1–2 Espinel-Ingroff et al 2001
Fusarium solani (77) 0.25–>16/2–>16 2–>8 Espinel-Ingroff et al 2001; Minassian et al 2003; Radford et al 1997
Fusarium verticillioides (3) 1–8 1
a Minassian et al 2003
Fusarium spp (24) 0.25–>8 8–>8 Diekema et al 2003; Marco et al 1998
Paecilomyces boydii (6) 0.25–0.5 0.33
b Espinel-Ingroff 1998
Paecilomyces lilacinus (8) 0.12–1/1–4 0.5 Espinel-Ingroff et al 2001; Radford et al 1997
Paecilomyces variotii (2) 4–>64 Radford et al 1997
Paecilomyces spp (7) 0.03–2 Diekema et al 2003; Marco et al 1998
Scedosporium apiospermum (60) 0.03–2 0.25–2 Carrillo and Guarro 2001; Cuenca-Estrella et al 1999; Meletiadis
 et al 2002; Minassian et al 2003; Radford et al 1997
Scedosporium prolificans (154) 0.06–32/2–>8 4–16 Carrillo and Guarro 2001; Cuenca-Estrella et al 1999; Espinel-
Ingroff et al 2001; Meletiadis et al 2002; Minassian et al 2003;
Radford et al 1997
Scopulariopsis brevicaulis (2) 4–8 Radford et al 1997
Scopulariosis brumptii (3) 2–8 Espinel-Ingroff et al 2001
Pseudallescheria boydii (59) 0.06–1/0.25–>16 0.5 Espinel-Ingroff et al 2001; Marco et al 1998
Trichoderma longibrachiatum (5) 2/4 2 Espinel-Ingroff et al 2001
Thrichoderma spp (1) 0.25 Marco et al 1998
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different authors (a total of 536 isolates), only voriconazole
MIC values of ≥4 µg/mL were obtained against some isolates
of Exophiala jeanselmei, Hormonema dematioides,
Phaeoscleria dematioides, Scolecobasidium constrictum,
and S. humicola. The highest MIC90 or geometric mean MIC
reported for this group was 1.25 µg/mL. Fungicidal activity
has also been observed against Fonsecaea pedrosoi,
Phaeoacremonium parasiticum, and Wangiella dermatitidis.
Furthermore, all 44 basidiomycetes isolates were inhibited
by ≤1 µg/mL voriconazole (Table 5).
The fungicidal activity of voriconazole against the 532
dimorphic fungi reviewed was species dependent. Whereas
some isolates of Blastomyces dermatitidis and Sporothrix
schenckii have voriconazole MICs of ≥16 µg/mL, the MIC90
for the majority of species is 0.25µg/mL, and ≥16µg/mL
for S. schenckii. However, voriconazole showed poor or no
in vitro activity against the 182 isolates of zygomycetes
evaluated.
Among hyphomycete fungi, voriconazole is active
against the most clinically important pathogens (Aspergillus
spp, Fusarium spp, and Penicillium marneffei). Moreover,
it is effective against the two well-documented itraconazole-
resistant A. fumigatus (Espinel-Ingroff et al 2002). The
MIC90 of voriconazole was usually ≤1 µg/mL for most of
the Aspergillus spp evaluated. Notably, voriconazole shows
good in vitro activity against A. terreus, a species resistant
to amphotericin B. Nevertheless, the activity of voriconazole
against Fusarium spp, Paecilomyces spp, and Scedoporium
spp is species dependent, with MICs ranging from 8 µg/mL
to 16 µg/mL for non-Fusarium solani species and
Paecilomyces variotii (Table 5).
In summary, voriconazole has shown in vitro activity
against the most common species of yeast isolates, including
both intrinsically and secondarily fluconazole-resistant
species. Cross-resistance among triazoles is reported only
for the RR phenotype. Notably, voriconazole is active
against both RR and RS phenotypes of C. krusei, suggesting
different mechanisms of resistance to azoles in this species.
Voriconazole also displays activity against most species of
filamentous fungi that cause systemic or subcutaneous
mycoses, such as Aspergillus spp, S. apiospermum,
Fusarium spp, P. marneffei, and most of the dematiaceus
moulds. However, voriconazole has poor activity against
zygomycetes.
Animal studies
The efficacy of voriconazole in animal models of invasive
infections of Aspergillus spp (pulmonary, disseminated,
endocarditic) (George et al 1996; Martin et al 1997; Murphy
et al 1997; Chandrasekar et al 2000; Kirkpatrick et al 2000),
Scedosporium spp (Capilla et al 2003; Capilla and Guarro
2004), B. dermatitidis (Sugar and Liu 2001), and C. krusei
(Ghannoum et al 1999) has been widely studied. In all
studies, the efficacy of voriconazole was similar to, or better
than, that of the antifungal agent compared (amphotericin
B, caspofungin, fluconazole, or itraconazole).
Zygomycetes (182)
Absidia corymbifera (20) 4–>16/16–>16 16–>16 Espinel-Ingroff et al 2001; Minassian et al 2003
Absidia elegans (1) 16 16 Dannaoui et al 2003
Absidia spp (25) 2–16 16 Dannaoui et al 2003; Gil-Lamaignere et al 2005
Apophysomyces elegans (1) 16 McGinnis et al 1998
Cunninghamella bertholletiae (1) 32 32 Dannaoui et al 2003
Cunninghamella spp (15) 8–>16 >16a Gil-Lamaignere et al 2005; Minassian et al 2003
Mucor hiemalis (1) >32 McGinnis et al 1998
Mucor spp (23) 1–>32 16–>32 Dannaoui et al 2003; Diekema et al 2003; Gil-Lamaignere et al
2005; Minassian et al 2003
Rhizomucor pusillus (2) 2–16 5.66
b McGinnis et al 1998
Rhizomucor spp (10) 4 16 Dannaoui et al 2003; Minassian et al 2003
Rhizopus arrhizus (23) 4–>32/8–>16 16 Espinel-Ingroff et al 2001
Rhizopus spp (60) 1–>16 8–16 Dannaoui et al 2003; Diekema et al 2003; Gil-Lamaignere et al
2005; Marco et al 1998; Minassian et al 2003
Abbreviations: MIC, range of minimal inhibitory concentrations (µg/mL); MFC, minimal fungicidal concentration (µg/mL); MIC90, range of minimal inhibitory
concentrations at which 90% of isolates are inhibited (µg/mL); 
a, modal value; 
b, geometric mean.
Table 5 Continued
Genus and Species (No. tested) MIC/MFC MIC90 ReferenceTherapeutics and Clinical Risk Management 2006:2(2) 143
Voriconazole in invasive mycoses
When the activity of voriconazole was studied in
combination with amphotericin B, caspofungin, or
micafungin, no antagonism was observed (Chandrasekar et
al 2004). Furthermore, the combination therapy of
voriconazole plus caspofungin was more effective than
monotherapy in a neutropenic guinea pig model of invasive
aspergillosis (Kirkpatrick et al 2002).
Clinical use against fungal
pathogens
Aspergillosis
Invasive aspergillosis is a serious, life-threatening infection
with a high attributable mortality rate (65%–90%) in
immunocompromised patients. Furthermore, the incidence
of this infection has increased substantially over the past
two decades. Voriconazole has been used as the primary
therapy and as a salvage therapy in a number of studies of
immunosuppressed patients with invasive aspergillosis, with
encouraging results (Table 6). The largest of these studies,
a randomized clinical trial, compared voriconazole with
amphotericin B as the primary therapy in 277 hematological
patients with invasive aspergillosis. At week 12, a successful
outcome was observed in 53% of patients given
voriconazole and 32% of those given amphotericin B. The
survival rate at 12 weeks showed a significant advantage
for the voriconazole group with 71% survival compared with
58% in the amphotericin group (Herbrecht et al 2002).
In an open, noncomparative, multicenter study of
immunocompromised patients with invasive aspergillosis,
Table 6 Global response to voriconazole of patients with invasive aspergillosis in clinical studies
Nature of Total
voriconazole number of
treatment patients Main underlying disease Outcome Reference
Comparative study of 277 Allogeneic HSCT, hematological Successful in 53% Herbrecht et al 2002
voriconazole vs malignancy voriconazole group
amphotericin B vs 32% amphotericin B
Salvage therapy 142 Hematological malignancy Satisfactory in 43.7% Perfect et al 2003
Primary therapy in 53% 116 Neutropenia, allogeneic HSCT Successful in 48% Denning et al 2002
Salvage therapy in 48% 102 Neutropenia Successful in 53% de Pauw 1999
Retrospective cohort 83 Allogeneic HSCT, hematological Successful in 44.2% Steinbach et al 2004
study of Aspergillus malignancy, SOT, solid tumor
terreus invasive infection
Retrospective study 81 Hematological malignancy, Complete or partial Schwartz et al 2005
of CNS aspergillosis allogeneic HSCT response in 35%
Salvage therapy 51 Hematological malignancy, relapsed Successful in 41% Schlamm et al 2000
malignancy, neutropenia
Compassionate or 42 Chronic granulomatous disease, Successful in 43% Walsh, Lutsar, et al 2002
salvage therapy in hematological malignancy
children
Open study 36 Immunosuppression Successful in 75% Denning et al 1995
Compassionate therapy 35 SOT, HSCT, hematological malignancy Complete or partial Baden et al 2003
response in 53%
Open-label, 33 Critically ill Successful in 50% Alvarez-Lerma et al 2005
noncomparative,
observational study
Primary therapy in 50% 25 Nonneutropenia Successful in 53% Dupont et al 1995
Retrospective study 20 Immunosuppression Successful in 55% Mouas et al 2005
of bone aspergillosis
Salvage therapy 24 Hematological malignancy, HSCT Successful in 41% Green et al 2000
Retrospective study, 12 Hematological malignancy in 52% Successful in 66% Diaz-Pedroche et al 2005
compassionate or
salvage therapy
Compassionate or 7 Chronic granulomatous disease, Successful in 43% Cesaro et al 2003
salvage therapy hematological malignancy
in children
Retrospective study 4 Neutropenia Successful in 75% Caillot et al 1997
Salvage therapy 5 SOT recipients Successful in 60% Fortun et al 2003
Abbreviations: HSCT, hematopoietic stem-cell transplant; SOT, solid organ transplant.Therapeutics and Clinical Risk Management 2006:2(2) 144
Pemán et al
treatment with voriconazole was effective in 48% of cases
(Denning et al 2002). In two large studies of patients
refractory to or intolerant of treatments for fungal infections,
efficacy rates of 44% and 53% (de Pauw 1999; Perfect et al
2003, respectively) were reported for aspergillosis treated
with voriconazole.
In a recent, retrospective cohort study of patients with
A. terreus infections, in which voriconazole was compared
with other antifungal therapies, a decrease in mortality at
12 weeks was observed (55.8% vs 73.4%, respectively) in
those patients who received voriconazole (Steinbach et al
2004).
One of the most important problems in the treatment of
cerebral aspergillosis is the poor penetration of antifungal
agents into the central nervous system (CNS). However,
treatment with voriconazole results in measurable drug
levels in the CSF, which may exceed the MIC for Aspergillus
spp (Lutsar et al 2003). In a retrospective study, patients
with CNS aspergillosis were treated with voriconazole as
salvage therapy, for a median of 51 days. Complete and
partial responses were observed in 35% of all patients, with
a survival rate of 31% (Troke et al 2003).
Recently, a global response rate of 55% was also
recorded in 20 patients with bone aspergillosis treated with
voriconazole (18 as a salvage therapy and two as a primary
therapy) (Mouas et al 2005). Similar results have been
reported in other studies involving bone-marrow and solid-
organ transplant recipients, critically ill patients,
hematological malignancies, chronic granulomatous disease,
and other immunocompromising conditions (Table 6)
(Caillot et al 1997; Walsh, Lutsar, et al 2002; Alvarez-Lerma
et al 2005; Diaz-Pedroche et al 2005).
Numerous case reports have also been published
documenting the successful use of voriconazole in the
treatment of invasive aspergillosis in hematological
malignancies, both in pediatric patients (Cesaro et al 2003;
Chow et al 2003; Shouldice et al 2003; Lassaletta et al 2004;
Rosen-Wolff et al 2004) and adults (‘t Hek et al 1998;
Verweij et al 1999; Hwang et al 2001; Mattei et al 2002;
Garbino et al 2003; Sambatakou et al 2003; Azzola et al
2004; Eibl et al 2004).
The efficacy of voriconazole in the treatment of
Aspergillus spp infections has also been confirmed in a
number of individual case reports, including infections of
the skin (La Nasa et al 2004), bone (Swift and Denning
1998; Stratov et al 2003), mediastinum (Levin et al 2004),
eye (Aliyeva et al 2004; Bethell et al 2004), prosthetic valve
(Reis et al 2005), and CNS (Moling et al 2002; de Lastours
et al 2003; Marbello et al 2003; Tattevin et al 2004; Schwartz
et al 2005). Furthermore, recently published data suggest
that voriconazole is a useful adjunctive therapy for allergic
bronchopulmonary aspergillosis in children with cystic
fibrosis (Hilliard et al 2005).
According to these studies, voriconazole is likely to
become the new standard therapy for invasive aspergillosis.
Candidiasis
Infections due to Candida spp are an important cause of
morbidity and mortality in immunocompromised patients.
Furthermore, Candida spp are the fourth most common
source of nosocomial bloodstream infections in the USA.
Clinical findings suggest that voriconazole may become an
effective therapeutic option for candidiasis because of
increases in fluconazole-susceptible or -resistant Candida
isolates. For instance, voriconazole, alone or with
caspofungin, was useful in the management of endogenous
Candida endophthalmitis (Breit et al 2005). The successful
treatment with voriconazole of keratitis, retinitis, or
chorioretinitis due to Candida spp has also been reported
(Granados et al 2004; Jang et al 2005; Varma et al 2005).
There are several documented cases of a successful response
to voriconazole in the treatment of infections caused by
uncommon or fluconazole-resistant species (Corpus et al
2004; Fabry et al 2005): non-C. albicans peritonitis in
peritoneal dialysis patients (Kleinpeter 2004), and Candida
infection of the subacromial bursa (Khazzam et al 2005).
In a multicenter, randomized, double-blind, double-
dummy study, voriconazole was at least as effective as
fluconazole in the treatment of oral and esophageal
candidiasis in immunocompromised patients (Ally et al
2001). Previously, voriconazole had been used successfully
as a salvage therapy in fluconazole-refractory mucosal
candidiasis in HIV-positive patients (Hegener et al 1998).
In systemic candidiasis, a 56% complete or partial
cure rate was observed with voriconazole in patients
intolerant of other antifungal agents or with refractory
infections (Ostrosky-Zeichner, Oude Lashof, et al 2003).
A similar global response rate (55%) for invasive
candidiasis was also reported in a large salvage therapy
study that investigated the effectiveness of voriconazole
against a wide range of invasive mycoses (Perfect et al
2003). Most recently, data from a large multicenter,
randomized trial has been published that compares the
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comprising conventional amphotericin B followed by
fluconazole in 422 nonneutropenic patients with
candidemia (Kullberg et al 2005). At the primary end
point (12 weeks after the end of therapy), voriconazole
was not inferior to the amphotericin B/fluconazole
regimen. In the secondary analysis, the success rate of
voriconazole at the end of therapy was 65%. Voriconazole
cleared the bloodstream of Candida as rapidly as
amphotericin B, followed by fluconazole, and with fewer
toxic effects. The majority of infections were due to non-
Candida albicans species (55%) but there was a similar
distribution of species in the two treatment groups. The
successful response rates were similar between the
voriconazole and amphotericin B/ fluconazole arms,
except for C. tropicalis. The proportion of patients with
C. tropicalis that responded satisfactorily was
substantially higher in the voriconazole treatment group,
although these isolates were also susceptible to
amphotericin B.
The efficacy of voriconazole in the treatment of invasive
candidiasis in pediatric patients has also been reported on a
compassionate-use basis (Walsh, Lutsar, et al 2002) and as
the primary therapy for a preterm infant with a disseminated
fluconazole-resistant C. albicans infection (Muldrew et al
2005).
The broader activity spectrum of voriconazole, its greater
safety than that of amphotericin B, and the availability of
intravenous and oral formulations make voriconazole an
important new treatment option for invasive Candida
infections.
Scedosporium/Pseudallescheria infections
Scedosporium apiospermum and S. prolificans, which are
generally amphotericin B resistant, have emerged as major
pathogens among immunocompromised patients. The
clinical experience of voriconazole treatment for
scedosporiosis and pseudallescheriasis usually reflects the
in vitro results, showing excellent activity against S.
apiospermum but only modest activity against S. prolificans,
organisms found mostly in Spain and Australia (Cuenca-
Estrella et al 1999; Carrillo and Guarro 2001). The
usefulness of voriconazole therapy in soft-tissue and
subcutaneous infections of S. apiospermum has been
reported in several immunocompromised patients (Montejo
et al 2002; Bosma et al 2003; Schaenman et al 2005). Post-
traumatic S. apiospermum keratitis or endophthalmitis have
also been successfully treated with systemic and topical
voriconazole (Fortun et al 2003; Nulens et al 2003; Figueroa
et al 2004; Hernandez et al 2004). One of the rare cases of
chronic vertebral osteomyelitis caused by S. apiospermum
was treated with salvage surgery and long-term voriconazole
therapy, leading to an adequate two-year outcome (German
et al 2004).
The effectiveness of voriconazole in the treatment of S.
apiospermum invasive pulmonary infections in children with
hematological malignancies has also been reported (Jabado
et al 1998; Walsh, Lutsar, et al 2002; Klopfenstein et al
2003). Recently, chronic meningitis caused by S. apio-
spermum was documented in a woman with no predisposing
condition. She was treated with an entirely oral course of
voriconazole for 12 months; two years after the cessation
of therapy, the patient remained symptom-free (Danaher and
Walter 2004). In recent years, several publications have
reported successful outcomes when disseminated S.
apiospermum infections were treated with voriconazole in
patients with different underlying conditions: corticosteroid
therapy (Munoz et al 2000), solid-organ transplant recipient
(Fortun et al 2003; Ahmed et al 2004; Husain et al 2005),
acute myeloid leukemia (Girmenia et al 1998), and failure
or intolerance of standard antifungal therapies (Baden et al
2003).
The efficacy of voriconazole in the treatment of deep
infections caused by Pseudallescheria boydii (sexual form
of S. apiospermum) has also been reported: brain abscess
(Nesky et al 2000; Castiglioni et al 2002), pulmonary
empyema (Perlroth and Miller 2004), pneumonia (Chaney
et al 2004), fungus ball (Garci et al 2003), osteomyelitis
(Kanafani et al 2004), and chronic meningitis (Poza et al
2000).
S. prolificans is highly resistant to antifungal agents, both
in vitro and in vivo. However, individual case reports have
noted successful outcomes with voriconazole treatment for
S. prolificans osteomyelitis and disseminated infections in
combination with surgery (Studahl et al 2003), caspofungin
(Steinbach et al 2003), or terbinafine (Gosbell et al 2003;
Howden et al 2003).
Fusarium infections
Although Fusarium infections are known to cause major
morbidity and mortality in immunocompromised hosts,
the clinical data currently available on the efficacy of
voriconazole in the treatment of these infections are
promising. Severe hypopyon keratitis (Reis et al 2000)
and a corneal abscess (Polizzi et al 2004), both causedTherapeutics and Clinical Risk Management 2006:2(2) 146
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by F. solani, that did not respond to common antifungal
agents, underwent clinical cures with topical and systemic
voriconazole therapy. The first two cases of Fusarium
soft-tissue infection treated successfully with
voriconazole were reported in 2004: a proven F. dimerum
infection of the foot with a possible pulmonary infection
10 days after a sibling allogeneic stem-cell transplant
(Bigley et al 2004), and a proven Fusarium spp nodular
lesion on the left arm of a woman with Evans syndrome
(Guimera-Martin-Neda et al 2004).
There are several documented cases of disseminated
Fusarium infections that responded successfully when
voriconazole was added to the therapy: a F. solani
infection with skin and cerebellar lesions in a neutropenic
patient (Vincent et al 2003); a disseminated F. oxysporum
infection with skin localization in a woman with a relapse
of B-acute leukemia during induction chemotherapy
(Durand-Joly et al 2003); a disseminated Fusarium spp
infection with skin manifestations in a severely
neutropenic and immunocompromised host (Consigny
et al 2003); a three-year-old girl with severe aplastic
anemia and skin, chest wall, and splenic lesions caused
by F. oxysporum (Rodriguez et al 2003); and a 10-year-
old neutropenic girl, treated for acute myeloid leukemia,
with disseminated fusariosis uncontrolled by
amphotericin B (Petit et al 2005). An immuno-
compromised child with F. solani endocarditis survived
after treatment with voriconazole, even though the
organism was resistant in vitro to all available antifungal
agents (Guzman-Cottrill et al 2004). Two studies of
salvage therapies with voriconazole for less common
fungal infections reported satisfactory global responses
in seven (50%) of 14 patients (Baden et al 2003; Perfect
et al 2003). This proportion is similar to that in pooled
data presented to the FDA, wherein nine (43%) of 21
patients with fusariosis had a complete or partial response
to voriconazole provided on a com-passionate-use basis.
In contrast, a recent publication reported a patient with
acute leukemia who suffered breakthrough fusariosis
while receiving voriconazole (Cudillo et al 2005).
However, reports of the successful use of voriconazole
therapy in patients with fusariosis and in vitro studies
showing lower MIC values for voriconazole against
Fusarium species than for itraconazole or amphotericin
B suggest a potential role for voriconazole as a life-
saving therapy for immunocompromised hosts with
Fusarium infections.
Acremonium infections
Acremonium spp are ubiquitous saprobes in the soil and an
infrequent cause of infections in immunocompetent and
immunocompromised hosts. Two fungemia episodes caused
by Acremonium spp were successfully treated with
voriconazole after the failure of amphotericin B therapy
(Mattei et al 2003). Another successful outcome has been
reported after oral voriconazole treatment for disseminated
Acremonium infection associated with pacemaker-related
endocarditis and endophthalmitis in a patient with no
underlying condition (Heitmann et al 1997). Thus,
voriconazole can be considered an effective salvage therapy
for invasive Acremonium infections.
Other organisms
Voriconazole may also become a therapy option for less
common fungal pathogens. Case reports have suggested that
voriconazole is clinically efficacious in disseminated
Coccidioides immitis infections. A patient with disseminated
nonmeningeal coccidioidomycosis, clinically unresponsive
to a prolonged course of amphotericin B, responded
favorably to voriconazole monotherapy without adjunctive
surgical intervention (Prabhu et al 2004). Another patient
with coccidiodal meningitis responded to high-dose
voriconazole therapy after the failure of fluconazole
treatment (Cortez et al 2003).
Eleven HIV-infected patients from Thailand had
disseminated Penicillium marneffei infections; eight of the
nine assessable patients responded successfully to
voriconazole (Schlamm and Supparatpnyo 2003). Moreover,
the high response rate among patients with penicilliosis
(90%) and phaeohyphomycosis (100%) to voriconazole
when it is used as a salvage therapy suggests that this drug
has a significant role in the management of refractory or
less common fungal infections (Perfect et al 2003).
A case of disseminated Paecilomyces lilacinus,
successfully treated with voriconazole, has been described
in an AIDS patient. The strain isolated was susceptible in
vitro to voriconazole (MIC, 0.12 mg/L) but resistant to
itraconazole (MIC, 2 mg/L) and amphotericin B (MIC,
>8 mg/L), demonstrating a good correlation between the in
vivo and in vitro data (Martin et al 2002).
Clinical use in patients at risk
Hematological patients
The role of voriconazole as an empirical treatment for
patients with febrile neutropenia remains unresolved, andTherapeutics and Clinical Risk Management 2006:2(2) 147
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in fact, voriconazole is currently not licensed for this
indication. The results of a large, international, multicenter,
randomized study that compared voriconazole with
liposomal amphotericin B for the empirical treatment of
febrile neutropenic patients have been controversial (Walsh,
Pappas, et al 2002). The analysis was performed on a
modified intent-to-treat basis for a total of 837 enrolled
febrile neutropenic patients (72% with hematological
malignancies), 415 of whom received voriconazole and 422
of whom received liposomal amphotericin B. According to
the predefined end point of this study (noninferiority),
voriconazole did not achieve this goal relative to liposomal
amphotericin B; the overall success rates were 26% in
voriconazole-treated patients and 30.6% in liposomal
amphotericin-B-treated patients. Complete or partial
response rates of the 19 patients with baseline fungal
infections favored liposomal amphotericin B (66.7% vs
46.2% for voriconazole). However, breakthrough fungal
infections occurred in eight patients (1.9%) in the
voriconazole group compared with 21 patients (5%) in the
liposomal amphotericin B group (p = 0.02). Moreover,
patients receiving voriconazole in the stratified cohort with
a high risk of fungal infection (those with allogeneic
transplants or relapsed leukemia) demonstrated an even
more pronounced reduction in invasive fungal infections
than patients receiving liposomal amphotericin B (two of
143 [1.4%] vs 13 of 141, [9.2%], respectively; p=0.003).
Furthermore, the voriconazole group had fewer cases of
severe infusion-related reactions (p<0.01) or nephrotoxicity
(p<0.001), although the number of deaths was similar in
both groups. Based on these results, voriconazole did not
receive FDA approval as an empirical antifungal therapy,
leading to the paradox that an agent licensed and considered
to be the antifungal agent of choice for the treatment of
documented Aspergillus infection was not deemed suitable
for the basic objective of an empirical antifungal therapy
(to prevent an invasive fungal infection or treat an occult
invasive fungal infection that is not documented). This is
attributable to one of the potential drawbacks in using
defervescence as a criterion in the composite end point of
success, because other causes of fever can confound the
assessment of a true antifungal effect. Thus, on the basis of
currently available evidence, voriconazole appears to be a
suitable alternative to conventional liposomal amphotericin
B as an empirical antifungal therapy in patients with
persistent fever and neutropenia (Klastersky 2004).
Once a diagnosis of invasive fungal infection is made,
the use of voriconazole for the treatment of hematological
patients is as recommended above, according to the causal
organism. Another important issue in hematological patients
is that any delay in the scheduled treatment of the underlying
malignancy until complete resolution of a probable or proven
fungal infection may have major implications for the
prognosis. In this context, secondary prophylaxis with
voriconazole was successful in 11 patients with acute
leukemia with previous Aspergillus (n = 10) or Candida
(n=1) infections. Nine patients were scheduled for allogeneic
stem-cell transplantation, and two for consolidation therapy
for acute leukemia. They received voriconazole (400 mg/
day) intravenously or orally for 44–245 days. None of the
patients had a relapse of the fungal infection, and the
scheduled treatments for leukemia were delayed only once
(Cordonnier et al 2004). This small but homogeneous series
indicates that voriconazole may be useful in preventing
fungal relapse in leukemic patients during at-risk periods.
However, caution is required when prescribing voriconazole
to hematopoietic stem-cell transplant recipients. It is
noteworthy that several antineoplastic agents commonly
used in the conditioning regimen are metabolized by the
CYP3A4 enzyme system. If a patient receiving voriconazole
for a preexisting fungal infection is scheduled to undergo a
hematopoietic stem-cell transplant, voriconazole should be
stopped at least 30 hours prior to the preparative regimen,
and restarted at least 48 hours after conditioning
chemotherapy (usually on day +1). Of course, non-azole
antifungals can be administered during the preparative
regimen. The main clinically significant drug interactions
with voriconazole are summarized in Table 3.
Critically ill patients
Approximately 10.4% of the infectious episodes in an
Intensive Care Unit (ICU) are related to a Candida spp
infection, most of which are hospital-acquired (Alberti et al
2002). This rate may be an underestimation because at least
4% of deaths in ICUs present with an unexpected fungal
infection on postmortem examination (Dimopoulos et al
2004). Furthermore, ICU admission itself has become an
independent risk factor for Candida infection (Puzniak et
al 2004; Tortorano et al 2004), and has also been associated
with significant mortality among critically ill patients
(Kalenic et al 2001).
The choice of the best first-line treatment for candidemia
remains controversial, especially in critically ill patients.
Successful therapy with compassionate use of voriconazole
for the treatment of candidemia and invasive candidiasis inTherapeutics and Clinical Risk Management 2006:2(2) 148
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patients intolerant of or refractory to other antifungal agents
has been reported (Ostrosky-Zeichner, Oude Lashof, et
al 2003). This study showed that voriconazole may be a
suitable agent for salvage treatment of invasive
candidiasis, even in the setting of previous azole exposure
and C. krusei infection. These findings have also been
confirmed by two Spanish studies (Munoz et al 2005;
Pemán et al 2005).
A Spanish observational multicenter study (Alvarez-
Lerma et al 2005) assessed the clinical use and tolerability
of voriconazole for the treatment of fungal infections in
critically ill patients. The prescription of voriconazole
was based on the presence of an episode of fungal
infection, and identification of the genus and species of
the causative pathogen, which had previously been treated
with other antifungal drugs. Voriconazole was effective
in 50% of patients. The drug was well tolerated and
treatment discontinuation because of adverse events was
not necessary.
Recently, the first randomized, prospective,
multicenter study of nonneutropenic patients with
candidemia treated with voriconazole or amphotericin B
deoxycholate has shown equivalent results for the
efficacy and mortality in both treatment arms (Kullberg
et al 2005). The incidence of renal dysfunction was
significantly lower in the voriconazole group. Although
the incidence of visual disturbances was slightly higher
in this group, these side effects were usually transient
and resolved after the patient had become tolerant of the
drug or the drug had been discontinued. About half the
patients included in this study were admitted to an ICU.
The only limitation to the intravenous administration of
voriconazole in critically ill patients could be the
accumulation and toxicity of its excipient (cyclodextrin)
in patients with severe renal dysfunction. Data for patients
undergoing renal replacement therapy are lacking.
The efficacy and safety of voriconazole has also been
demonstrated in the treatment of invasive aspergillosis
and other less common mould infections (Herbrecht et al
2002; Perfect et al 2003). These results provide sufficient
evidence to justify the use of voriconazole as a first-line
therapy, alone or in combination, in suspected or proven
invasive aspergillosis or other mould infections in ICU
settings.
The encouraging clinical experience with this drug
suggests that voriconazole is a new therapeutic alternative
in critically ill patients, not only as a salvage treatment,
but also as a first-line option in suspected or proven
Candida and Aspergillus infections.
Other patients at risk
Solid-organ transplantation
Before voriconazole came into use, mortality due to invasive
mould infections in solid-organ transplant (SOT) recipients
was very high, despite therapy with amphotericin B.
Preliminary results for voriconazole administered on a
compassionate-use basis in patients with these infections
has been promising. Voriconazole was administered for an
average of 80 days to four patients with invasive A.
fumigatus infection and to another patient with invasive
ocular S. apiospermum infection. All of these patients had
been treated previously with a lipid formulation of
amphotericin B, and cultures were persistently positive
despite a cumulative dose of 3 g (Fortun et al 2003). A
clinical response to voriconazole was observed in all patients
(three with a complete response; a partial response in two),
and a microbiological response was observed in all but one
patient. Furthermore, a good correlation between the MIC
of voriconazole and outcome was observed. However, an
increase in the levels of immunosuppressive drugs
(tacrolimus or cyclosporine) was detected in all patients.
In another study (Baden et al 2003) in which
voriconazole was used in a compassionate release program,
35 (78%) of patients had invasive Aspergillus, three (7%)
had Fusarium infections, and two (4%) had Scedosporium
infections. Overall response rates were nine (20%) complete
responses, 17 (38%) partial responses, 15 (33%) failures,
and four (9%) patients were intolerant. Seven of the eight
(88%) patients with sinus or CNS disease exhibited
stabilization of the invasive fungal infection. In a total of
9 128 days of therapy, only four serious adverse events that
were considered possibly or probably drug-related were
observed in two patients.
Therefore, voriconazole may be considered an effective
and safe therapy for the treatment of invasive mould
infections in SOT recipients. However, to avoid toxicity with
this drug, the doses of immunosuppressive drugs must be
reduced (Table 3).
HIV Infection or AIDS
A multicenter, randomized, double-blind, double-dummy
study compared voriconazole with fluconazole for the
treatment of esophageal candidiasis in 391
immunocompromised patients, most of whom had AIDSTherapeutics and Clinical Risk Management 2006:2(2) 149
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(Ally et al 2001). There was no difference between the two
groups with respect to cure, as determined by esophagoscopy
(98.3% of patients who received voriconazole and 95.1%
of patients who received fluconazole achieved cure).
Another small open-label, noncomparative study evaluated
the efficacy of voriconazole treatment for fluconazole-
refractory esophageal candidiasis in 12 patients with AIDS.
At day 7, six patients were cured, and the conditions of
three showed marked improvement; one other patient was
cured after two weeks of therapy, and there was no response
in two patients (Hegener et al 1998).
Voriconazole demonstrates excellent in vitro activity
against C. neoformans and achieves good CSF levels, but
no clinical trial results and only a few case reports of
voriconazole used against cryptococcal meningitis have
been published. In a case report of relapsing meningitis due
to a fluconazole-resistant C. neoformans in a patient with
advanced HIV infection, maintenance therapy with
voriconazole was unsuccessful in preventing a recurrence
of meningitis (Friese et al 2001). In another study that
focused on patients who were refractory to or intolerant of
treatment for fungal infections, the response rate for
cryptococcosis was 39% (Perfect et al 2003).
Thus, although voriconazole cannot be recommended
presently to treat HIV patients with disseminated or
meningeal cryptococcosis, its appropriate in vitro activity
against C. neoformans, suitable distribution in CSF and the
results obtained in the before mentioned studies make
voriconazole a promising drug in this setting. However, there
is need for more clinical and pharmacological studies in
HIV patients to assess pharmacokinetic effects, with or
without clinical relevance, derived from the co-
administration with protease inhibitors or other antiretroviral
drugs (efavirenz).
Pediatric patients
Children require higher doses of voriconazole than adults
to attain similar serum concentrations over time. Based on
limited pharmacokinetic analyses, it seems that a pediatric
dosage of 11 mg/kg administered every 12 hours is
approximately bioequivalent to an adult dose of 4 mg/kg
given every 12 hours (Steinbach 2005). The largest pediatric
report of voriconazole treatment was an open-label
compassionate-use study of 69 children between the ages
of nine months and 15 years for the treatment of an invasive
fungal infection (Walsh, Lutsar, et al 2002). The most
common underlying condition was hematological
malignancy, and the most frequent fungal pathogens were
Aspergillus spp (72%) and Scedosporium spp (14%). After
a mean period of voriconazole therapy of three months, 26
patients (45%) had a complete or partial response, four
patients had a stable response, and 25 failed therapy.
Stratifying the outcomes by pathogen revealed a complete
or partial response in 43% of patients with aspergillosis,
50% of patients with candidemia, and 63% of patients with
scedosporiosis. Only three patients were withdrawn from
the study because of toxicity. Common adverse effects
included elevation in transaminases or bilirubin, rash,
abnormal vision, and photosensitivity. The median plasma
concentration of voriconazole was 1 566 ng/mL for children
receiving ≥ 4 mg/kg intravenously bid, which is lower than
the median plasma concentrations (5 671 ng/mL) in a control
population of adults receiving 4 mg/kg bid. Another study
reported the experiences of seven children with
oncohematological malignancies and invasive aspergillosis
treated with voriconazole. Responses were complete in two
patients, partial in two patients, and stable in one; and there
was no response in the two other patients (Cesaro et al 2003).
Recently, treatment with voriconazole was reported in
eight pediatric patients with invasive bone aspergillosis, who
were mainly affected by chronic granulomatous disease, in
a worldwide series of 20 cases. At the end of therapy, four
(50%) patients had a satisfactory response (one complete
and three partial) to voriconazole (Mouas et al 2005).
These data lend support to the use of voriconazole in
the pediatric population as an alternative treatment for
invasive mycosis unresponsive to conventional antifungal
agents. However, additional clinical trials, including kinetic
studies, are required to further clarify the role of
voriconazole in the treatment of these infections in children.
Voriconazole in combination
therapies
The availability of new antifungal agents with single
mechanisms of action and improved tolerability has widened
the possibilities for the use of combination antifungal
therapies for difficult-to-treat opportunistic mycoses. Few
randomized clinical trials have examined the role of this
type of therapy for invasive mycoses, and no prospective
randomized trial of antifungal combinations has been
completed for invasive mould infections. The results of in
vitro studies and those with animal models suggest that
combination therapies with azoles and echinocandins mayTherapeutics and Clinical Risk Management 2006:2(2) 150
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have additive activity against Aspergillus species
(Kirkpatrick et al 2002; Perea et al 2002).
A recent study evaluated the outcomes of hematological
patients with pulmonary aspergillosis, who received either
voriconazole or a combination of voriconazole and
caspofungin as a salvage therapy. The combination therapy
was associated with an improved three-month survival rate
and with reduced mortality, compared with the voriconazole
monotherapy (Marr et al 2004). Apart from salvage therapy
results, further studies are required to show that a
combination therapy with voriconazole is better than a
single-drug treatment as the first-line therapy for invasive
aspergillosis in selected patients.
A growing number of case reports of combination
therapies for rare and emerging fungal infections (eg,
Scedosporium spp, Fusarium spp, Cladophialophora
bantiana) have described the beneficial action when
voriconazole was combined with either amphotericin B,
caspofungin, or terbinafine (Durand-Joly et al 2003;
Howden et al 2003; Steinbach et al 2003; Trinh et al 2003;
Cantón et al 2005). Combination therapies with voriconazole
may have value in select populations of patients at high risk
of death due to candidiasis, trichosponorosis, or
blastoschizomycosis, who are undergoing azole-based
prophylaxis, and high-risk patients with multiple-species
candidemia (Kontoyiannis and Lewis 2004). However, the
possible benefits of combination therapies with voriconazole
for disseminated cryptococcosis and invasive candidiasis
(or other emerging yeasts) must be clarified. At present, the
combination of amphotericin B plus flucytosine and
monotherapies with either fluconazole or caspofungin may
be more desirable in these contexts.
Most results and reports indicate that a combination
regimen may be an effective option in salvage therapies for
invasive aspergillosis and probably other difficult-to-treat
invasive fungal infections. Furthermore, the additive in vitro
interactions of voriconazole and echinocandins suggest a
great potential for such a combination therapy and confirm
the need for further investigations.
Ecological impact of voriconazole
use
Infections with voriconazole-resistant fungi may become
problematic, because organisms with decreased
susceptibility have been noted. Breakthrough fungal
infections occurred in 13 of 139 patients (9%) who received
voriconazole at the Fred Hutchinson Cancer Research Center
in Seattle, USA, during a five-year period. Candida glabrata
fungemia occurred in four patients and zygomycetes were
found in six patients (Imhof et al 2004). In a prospective
surveillance of 27 patients with zygomycosis at the M.D.
Anderson Cancer Center, nearly all patients either had
leukemia (n=14) or were allogeneic bone-marrow transplant
recipients (n=13). All the zygomycetes isolates (74% of
which were of the genus Rhizopus) were voriconazole-
resistant. Previous exposure to voriconazole was identified
by multivariate analysis as a significant risk factor for
zygomycosis (Kontoyiannis et al 2005). The association
between the use of voriconazole and zygomycosis is further
supported by several reports of breakthrough zygomycosis
in patients receiving voriconazole (Blin et al 2004;
Kobayashi et al 2004; Marty et al 2004; Mattner et al 2004;
Siwek et al 2004; Oren 2005; Vigouroux et al 2005).
Considering the growing number of reports, this issue
requires further attention. However, the definite causal
relationship between treatment with voriconazole and the
emergence of breakthrough infections caused by
zygomycetes must still be established in larger case series.
Although the use of voriconazole may have contributed to
the occurrence of zygomycosis, there are some data
indicating that the incidence of zygomycosis was increasing
before the introduction of voriconazole to clinical practice
(Kauffman 2004). It is possible that the control of a highly
aggressive infection such as invasive aspergillosis permits
patients to live long enough to develop a subsequent
breakthrough infection with persistent immunosuppression.
For instance, the first case of disseminated infection with
Prototheca zopfii was reported following an unrelated stem-
cell transplantation for leukemia, during the long-term
administration of voriconazole for the treatment of
pulmonary aspergillosis (Lass-Florl et al 2004).
Conclusions
Voriconazole is a new triazole with high oral bioavailability,
large volume of distribution (with excellent CNS
penetration), and elimination through hepatic metabolism
by cytochrome P450 isozymes.
The side-effect profile of voriconazole presents an
acceptable safety and tolerability spectrum. Transient visual
disturbances, liver enzyme abnormalities, and skin rashes
are the most frequently reported, but rarely lead to
discontinuation of treatment. The potential for drug–drug
interactions is high, because of the extensive hepatic
metabolism of voriconazole. Therefore, careful attention to
dosage is required, and its serum levels and the effects ofTherapeutics and Clinical Risk Management 2006:2(2) 151
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any interacting drug should be monitored. In young children,
it may be necessary to increase the dose administered
because of the rapid metabolism of the drug in this
population. Consistent with the high oral bioavailability, an
early switch from intravenous to oral therapy makes this
drug attractive for prolonged oral tratment after discharge
from the hospital.
Voriconazole has shown excellent in vitro activity
against a wide range of yeasts (including fluconazole-
resistant species and C. neoformans), dimorphic fungi,
opportunistic moulds (Aspergillus spp., Fusarium spp., and
S. apiospermum), and the amphotericin-B-resistant A.
fumigatus and A. terreus isolates. However, it lacks in vitro
activity against zygomycetes.
According to the in vitro and in vivo data reviewed,
voriconazole can be considered as the new standard
treatment for invasive aspergilliosis, either for primary or
salvage therapy. Furthermore, voriconazole displays clinical
efficacy in patients with fluconazole-resistant and
fluconazole-susceptible Candida invasive infections, bone
and CNS aspergillosis, and various refractory fungal
infections.
Additive in vitro interactions and good clinical response
in patients with invasive fungal infections treated with a
combination of voriconazole and echinocandins,
amphotericin B or terbinafine suggest a great potential for
such a combination therapy which needs to be confirmed in
further investigations.
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